<DOC>
	<DOCNO>NCT01340430</DOCNO>
	<brief_summary>The main purpose study confirm high pathologic complete response rate neoadjuvant chemotherapy FEC follow weekly paclitaxel concurrent trastuzumab Human Epidermal growth factor receptor2 ( HER2 ) positive non operable breast cancer</brief_summary>
	<brief_title>Neoadjuvant 5-fluorouracil , Epirubicin Cyclophosphamide ( FEC ) Followed Weekly Paclitaxel Trastuzumab Her2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Inclusion Criteria 1 . Performance StatusEstearn Cooperative Oncology Group ( ECOG ) 01 2 . Histologically confirm invasive breast cancer , 3 . Primary tumour great ≥ 2 cm diameter , measure clinical examination mammography echography Nuclear Magnetic Resonance ( NMR ) candidate neoadjuvant chemotherapy , 4 . Any N , 5 . No evidence metastasis ( M0 ) ; 6 . Over expression and/or amplification HER2 invasive component primary tumour accord one follow definition : 7 . 3+ expression immunohistochemistry ( IHC ) ( &gt; 30 % invasive tumour cell ) , 8 . 2+ 3+ ( 30 % le neoplastic cell ) overexpression IHC situ hybridization ( FISH/CISH ) test demonstrate Her2 gene amplication , 9 . Her 2 gene amplication FISH/CISH ( ratio &gt; 2.2 ) ; 10 . Known hormone receptor status 11 . Hematopoietic status : 1. absolute neutrophil count ≥ 1.5 x 109/L , 2. platelet count ≥ 100 x 109/L , 12 . Hepatic status : 1. serum total bilirubin ≤ 1.5 x ULN . In case know Gilbert 's syndrome high serum total bilirubin ( &lt; 2 x ULN ) allow , 2. aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 2.5 time ULN , 3. alkaline phosphatase ≤ 2.5 time ULN ; 13 . Renal status : a. Creatinine ≤ 2.0 mg/dL ; 14 . Cardiovascular : a. baseline leave ventricular ejection fraction ( LVEF ) ≥ 50 % measure echocardiography multigate acquisition scan ( MUGA ) ; 15 . For woman childbearing potential negative serum pregnancy test 16 . Written informed consent . 1 . Male gender 2 . Pregnant lactate woman 3 . Received prior treatment primary invasive breast cancer 4 . Known history uncontrolled symptomatic angina , clinically significant arrhythmia , congestive heart failure , transmural myocardial infarction , uncontrolled hypertension ( &gt; 180/110 ) , unstable diabetes mellitus , dyspnoea rest chronic therapy oxygen ; 5 . Active uncontrolled infection , 6 . Dementia alter mental status psychiatric condition would prevent stand render informed consent , 7 . Concurrent neoadjuvant cancer therapy ( chemotherapy , radiation therapy , immunotherapy , biologic therapy trial therapy ) , 8 . Previous concomitant malignancy within past 3 year EXCEPT adequately treat basal squamous cell carcinoma skin situ carcinoma cervix . 9 . Concurrent disease condition would make subject inappropriate study participation serious medical disorder would interfere subject 's safety .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>her2 positive breast cancer</keyword>
	<keyword>her2 positive non operable breast cancer</keyword>
	<keyword>her2 positive locally advanced breast cancer</keyword>
	<keyword>neoadjuvant trastuzumab</keyword>
	<keyword>pathologic complete response</keyword>
</DOC>